Charles River Laboratories Pre-Tax Income 2010-2024 | CRL
Charles River Laboratories annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Charles River Laboratories pre-tax income for the quarter ending December 31, 2024 was $-0.217B, a 203.87% decline year-over-year.
- Charles River Laboratories pre-tax income for the twelve months ending December 31, 2024 was $0.093B, a 83.98% decline year-over-year.
- Charles River Laboratories annual pre-tax income for 2024 was $0.093B, a 83.98% decline from 2023.
- Charles River Laboratories annual pre-tax income for 2023 was $0.581B, a 6.69% decline from 2022.
- Charles River Laboratories annual pre-tax income for 2022 was $0.623B, a 29.6% increase from 2021.
| Charles River Laboratories Annual Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2024 | $93 |
| 2023 | $581 |
| 2022 | $623 |
| 2021 | $481 |
| 2020 | $447 |
| 2019 | $304 |
| 2018 | $282 |
| 2017 | $297 |
| 2016 | $223 |
| 2015 | $195 |
| 2014 | $178 |
| 2013 | $138 |
| 2012 | $130 |
| 2011 | $133 |
| 2010 | $-334 |
| 2009 | $152 |
| Charles River Laboratories Quarterly Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-217 |
| 2024-09-30 | $91 |
| 2024-06-30 | $120 |
| 2024-03-31 | $99 |
| 2023-12-31 | $209 |
| 2023-09-30 | $113 |
| 2023-06-30 | $129 |
| 2023-03-31 | $131 |
| 2022-12-31 | $245 |
| 2022-09-30 | $123 |
| 2022-06-30 | $144 |
| 2022-03-31 | $111 |
| 2021-12-31 | $164 |
| 2021-09-30 | $123 |
| 2021-06-30 | $127 |
| 2021-03-31 | $66 |
| 2020-12-31 | $172 |
| 2020-09-30 | $135 |
| 2020-06-30 | $84 |
| 2020-03-31 | $55 |
| 2019-12-31 | $106 |
| 2019-09-30 | $73 |
| 2019-06-30 | $59 |
| 2019-03-31 | $66 |
| 2018-12-31 | $75 |
| 2018-09-30 | $73 |
| 2018-06-30 | $70 |
| 2018-03-31 | $63 |
| 2017-12-31 | $69 |
| 2017-09-30 | $73 |
| 2017-06-30 | $77 |
| 2017-03-31 | $78 |
| 2016-12-31 | $64 |
| 2016-09-30 | $53 |
| 2016-06-30 | $54 |
| 2016-03-31 | $52 |
| 2015-12-31 | $50 |
| 2015-09-30 | $53 |
| 2015-06-30 | $60 |
| 2015-03-31 | $32 |
| 2014-12-31 | $40 |
| 2014-09-30 | $44 |
| 2014-06-30 | $51 |
| 2014-03-31 | $43 |
| 2013-12-31 | $23 |
| 2013-09-30 | $43 |
| 2013-06-30 | $37 |
| 2013-03-31 | $36 |
| 2012-12-31 | $26 |
| 2012-09-30 | $28 |
| 2012-06-30 | $40 |
| 2012-03-31 | $35 |
| 2011-12-31 | $33 |
| 2011-09-30 | $25 |
| 2011-06-30 | $43 |
| 2011-03-31 | $33 |
| 2010-12-31 | $-373 |
| 2010-09-30 | $-8 |
| 2010-06-30 | $22 |
| 2010-03-31 | $24 |
| 2009-12-31 | $29 |
| 2009-09-30 | $40 |
| 2009-06-30 | $47 |
| 2009-03-31 | $35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $5.668B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.013B | 25.51 |
| Elevance Health (ELV) | United States | $93.532B | 12.07 |
| CVS Health (CVS) | United States | $83.782B | 10.41 |
| Cencora (COR) | United States | $56.393B | 20.47 |
| Natera (NTRA) | United States | $21.021B | 0.00 |
| DiDi Global (DIDIY) | China | $20.473B | 31.07 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.189B | 0.00 |
| CochLear (CHEOY) | Australia | $11.336B | 0.00 |
| Solventum (SOLV) | United States | $11.327B | 10.56 |
| ICON (ICLR) | Ireland | $10.910B | 10.14 |
| Revvity (RVTY) | United States | $10.864B | 18.34 |
| Doximity (DOCS) | United States | $10.660B | 55.44 |
| Viatris (VTRS) | United States | $10.056B | 3.20 |
| Medpace Holdings (MEDP) | United States | $8.300B | 22.04 |
| Avantor (AVTR) | United States | $8.164B | 11.86 |
| Sonic Healthcare (SKHHY) | Australia | $8.076B | 0.00 |
| HealthEquity (HQY) | United States | $7.797B | 38.36 |
| Amplifon S.p.A (AMFPF) | Italy | $4.736B | 25.00 |
| Bausch + Lomb (BLCO) | Canada | $3.852B | 22.71 |
| BrightSpring Health Services (BTSG) | United States | $3.804B | 35.21 |
| Sotera Health (SHC) | United States | $3.648B | 20.73 |
| Alignment Healthcare (ALHC) | United States | $3.110B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.950B | 33.84 |
| Concentras Parent (CON) | United States | $2.781B | 14.47 |
| Organon (OGN) | United States | $2.373B | 2.52 |
| Premier (PINC) | United States | $2.095B | 14.34 |
| Progyny (PGNY) | United States | $2.001B | 44.08 |
| Ardent Health Partners (ARDT) | United States | $1.857B | 7.93 |
| Agilon Health (AGL) | United States | $1.842B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.776B | 69.53 |
| GoodRx Holdings (GDRX) | United States | $1.634B | 35.50 |
| PACS (PACS) | United States | $1.503B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.243B | 9.46 |
| Teladoc Health (TDOC) | United States | $1.189B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.952B | 0.00 | |
| CareDx (CDNA) | United States | $0.790B | 12.33 |
| AMN Healthcare Services Inc (AMN) | United States | $0.748B | 5.92 |
| Nutex Health (NUTX) | United States | $0.735B | 14.39 |
| Embecta (EMBC) | United States | $0.710B | 4.86 |
| QDM (QDMI) | Hong Kong, SAR China | $0.671B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.518B | 13.73 |
| Sonida Senior Living (SNDA) | United States | $0.440B | 0.00 |
| Enhabit (EHAB) | United States | $0.407B | 38.29 |
| InnovAge Holding (INNV) | United States | $0.385B | 0.00 |
| LifeMD (LFMD) | United States | $0.341B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.338B | 0.00 |
| SBC Medicals (SBC) | United States | $0.323B | 0.00 |
| DocGo (DCGO) | United States | $0.239B | 9.75 |
| Oncology Institute (TOI) | United States | $0.197B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.177B | 0.00 |
| Beauty Health (SKIN) | United States | $0.132B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.095B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.089B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.087B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| OncoCyte (OCX) | United States | $0.083B | 0.00 |
| Biodesix (BDSX) | United States | $0.066B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| ModivCare (MODV) | United States | $0.020B | 7.10 |
| KindlyMD (KDLY) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |